Patent · US Active

Optimized antibodies that target CD19

US9803020B2 · kind B2 · utility

3Cited by

54References

24Claims

0Family size

Assignee

Xencor, Inc. · US

Inventors

Matthew Bernett · Monrovia, US
Seung Chu · Cypress, US
John Desjarlais · Pasadena, US
Sher Bahadur Karki · Pasadena, US
Gregory Alan Lazar · Los Angeles, US
Erik Weiking Pong · Temple City, US
John O. Richards · Duarte, US
Eugene Zhukovsky · West Hollywood, US

Key dates

Filing date	Aug 5, 2013
Grant date	Oct 31, 2017
Priority date	—
Expiry date	Dec 29, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcgγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.